Should we be monitoring patients on systemic dermatologic therapies for psychiatric adverse effects?: a proposed clinical framework
Open Access
- 29 September 2026
- journal article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1)
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database studyJournal of the American Academy of Dermatology, 2025
- Brodalumab: Six-Year US Pharmacovigilance ReportDermatology and Therapy, 2024
- Disproportionality analysis of psychiatric morbidities associated with isotretinoin using VigiBaseArchives of Dermatological Research, 2024
- Janus Kinase Inhibitors for Alopecia AreataJAMA Network Open, 2023
- Isotretinoin and the risk of psychiatric disturbances: A global study shedding new light on a debatable storyJournal of the American Academy of Dermatology, 2022
- Antihistamine safety in older adult dermatologic patientsJournal of the American Academy of Dermatology, 2022
- Risk of psychiatric disorders in patients taking isotretinoin: A nationwide, population-based, cohort study in TaiwanJournal of Affective Disorders, 2022
- JAK inhibitors in the treatment of atopic dermatitisJournal of Allergy and Clinical Immunology, 2021
- Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsJournal of the American Academy of Dermatology, 2018
- Neurological and Neuropsychiatric Adverse Effects of Dermatologic MedicationsCNS Drugs, 2016